Medigene AG
MDGEF · OTC
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $4,476 | $2,970 | $3,064 | $5,963 |
| % Growth | 50.7% | -3.1% | -48.6% | – |
| Cost of Goods Sold | $773 | $721 | $922 | $1,168 |
| Gross Profit | $3,703 | $2,249 | $2,142 | $4,795 |
| % Margin | 82.7% | 75.7% | 69.9% | 80.4% |
| R&D Expenses | $6,286 | $6,359 | $5,186 | $24,843 |
| G&A Expenses | $4,063 | $4,980 | $4,336 | $3,595 |
| SG&A Expenses | $4,063 | $4,996 | $4,340 | $3,698 |
| Sales & Mktg Exp. | $0 | $16 | $4 | $103 |
| Other Operating Expenses | -$7 | -$625 | $0 | $0 |
| Operating Expenses | $10,342 | $10,730 | $9,844 | $28,178 |
| Operating Income | -$6,639 | -$8,776 | -$7,373 | -$2,956 |
| % Margin | -148.3% | -295.5% | -240.6% | -49.6% |
| Other Income/Exp. Net | -$87 | -$117 | -$326 | -$456 |
| Pre-Tax Income | -$6,726 | -$8,893 | -$7,699 | -$23,845 |
| Tax Expense | $0 | $314 | -$729 | -$1,596 |
| Net Income | -$6,726 | -$9,207 | -$6,970 | -$22,249 |
| % Margin | -150.3% | -310% | -227.5% | -373.1% |
| EPS | -0.52 | -0.37 | -0.28 | -0.91 |
| % Growth | -40.5% | -32.1% | 69.2% | – |
| EPS Diluted | -0.52 | -0.37 | -0.28 | -0.91 |
| Weighted Avg Shares Out | 12,933 | 24,563 | 24,563 | 24,563 |
| Weighted Avg Shares Out Dil | 12,933 | 24,563 | 24,563 | 24,563 |
| Supplemental Information | – | – | – | – |
| Interest Income | $110 | $135 | $3 | $29 |
| Interest Expense | $0 | $548 | $0 | $516 |
| Depreciation & Amortization | $703 | -$68 | $671 | $20,341 |
| EBITDA | -$5,937 | -$8,844 | -$6,702 | $17,385 |
| % Margin | -132.6% | -297.8% | -218.7% | 291.5% |